期刊文献+

胸腺素α_1的生化特性及生物学活性的分析 被引量:3

Analysis of Biochemical Characteristics and Biological Activity of Thymosin α_1
下载PDF
导出
摘要 目的 :建立确定胸腺素α1纯度、分子量和等电点等生化特性和生物学活性检测的方法。方法 :应用高效液相色谱、三羟甲基甘氨酸 -SDS -聚丙烯酰胺凝胶电泳、等电聚焦 -聚丙烯酰胺凝胶电泳和3H -TdR掺入法 ,在致有丝分裂原存在的条件下 ,刺激小鼠脾淋巴细胞分裂增殖的能力。结果 :胸腺素α1的纯度为 98% ,其相对分子质量为 3 15 3 ,等电点为3 93,在 1 5 6~ 12 5 μg·mL-1剂量范围内脾淋巴细胞的增殖率明显提高。结论 :本文所用检测方法能准确地测定胸腺素α1的纯度、相对分子质量和等电点 ,有效地测定其生物学活性 。 Objective:To identify the quality of thymosin α 1(Tα 1),some biochemical characteristics such as purity,molecular weight(\%M\% r),isoelectric point( pI )and its biological activity were studied.Methods:High performance liquid chromatography(HPLC),Tricine-SDS-polyacrylamide gel electrophoresis(Tricine-SDS-PAGE),isoelectric focusing-polyacrylamide gel electrophoresis(IEF-PAGE) and 3H-TdR incorparation methods were developed to determine its purity,\%M\%\-r,\%pI\% and the proliferative respone of the mitogen ConA stimulated spleen lymphocytes respectively.Results:The purity of Tα 1 is about 98% and it has a molecular weight of 3 153 and a \%pI\% of 3 93.Furthermore,Tα 1 has biological activity to increase the proliferative respone of the mitogen ConA stimulated spleen lymphocytes of Balb/C mice.Conclusion:These methods are simple,rapid,reliable and stable to identify the quality of Tα 1.
出处 《药物分析杂志》 CAS CSCD 北大核心 2001年第4期237-240,共4页 Chinese Journal of Pharmaceutical Analysis
关键词 胸腺素Α1 高效液相色谱法 SDS-聚丙烯酰胺凝胶电泳 等电聚焦-聚丙烯酰胺凝胶电泳 生物活性 thymosin α 1,HPLC,SDS-polyacrylamide gel electrophoresis,IEF-polyacrylamide gel electrophoresis,biological activity
  • 相关文献

参考文献4

二级参考文献2

共引文献78

同被引文献37

  • 1CORDERO O J,SARANDESES C S,LOPEZ,et al.Prothymosin alpha receptors on peripheral blood mononuclear cells[J].FEBS Letters,1994,341(1):23.
  • 2BAUMANN C,BADAMXHIAN M,GOLDSTEIN A L,et al.Thymosin α1 antagonism of induced apoptosis of developing thymocytes requires the activation of multiple signal transduction pathways[J].FASEBJ,1996,10(2):A441.
  • 3LAU G K,NANJI A,HOU J,et al.Thymosin alpha1and famcidovir combination therapy activates T-cell response in patients with chronic hepatitis B virus infection in immune-tolerant phase[J].J Viral Hepat,2002,9(4):280.
  • 4MOSCARELLA S,BUZZELI G,ROMANELLI R G,et al.Interferon and thymosin combination therapy in naive patients with chronic hepatitis C:preliminary results[J].Liver,1998,18(2):366.
  • 5SHERMAN K E,SJOGREN M,CREAGER R L,et al.Combination therapy with thymosin α1 and interferon for the treatment of chronic hepatitis C infection:a randomized,placebo controlled double-blind trial[J].Hepatology,1998,27(5):1128.
  • 6GARACI E,LOPZ M,BONSIGNORE G,et al.Sequential chemoimmunotherapy for advanced non-small cell lung cancer using cisplatin,etopiside,thymosin α1 and interferon-α2a[J].Eur J Cancer,1995,31A(13/14):2403.
  • 7RASI G,TERZOLI E,LZZO F,et al.Combined treatment with thyrnosin α1 and low -dose interferon -alpha after dacarbazine in advanced melanoma[J].Melanoma Res,2000,10(1):1.
  • 8GARACI E,ROCCHIM G,PERRONI L,et al.Combination treatment with zidovudine,thymosin alphal and interferon-alpha in human immunodeficiency virus infection[J].Int J Clin Lab Res,1994,24 (1):23.
  • 9郭健新,平其能,张磊.胰岛素柔性脂质体经小鼠皮肤给药的降血糖作用[J].中国药学杂志,2001,36(1):35-38. 被引量:39
  • 10张红博,张春燕,胡屹伟.降纤酶治疗高粘血症的疗效及安全性[J].中国药师,2001,4(1):42-43. 被引量:3

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部